Aller au contenu principal
Accès ouvert déclaré 2026 article

Real‐World Effectiveness and Safety of a Tubeless Automated Insulin Delivery System With an Adaptive Control Algorithm ( APGO ) in Children and Adolescents With Type 1 Diabetes: A Multicentre Observational Study

0Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : it. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

AIM: Automated insulin delivery (AID) systems improve glycaemic outcomes in Type 1 diabetes; however, paediatric real-world data on newly introduced tubeless AID systems remain limited. We aimed to provide the first clinical evaluation of the A8 TouchCare Nano AID system with the APGO algorithm in children and adolescents with Type 1 diabetes. MATERIALS AND METHODS: In this prospective observational study, children and adolescents initiating TouchCare Nano AID therapy were followed for 6 months. Continuous glucose monitoring metrics were assessed at baseline and 1, 3 and 6 months. The primary outcome was change in time in range (TIR, 70-180 mg/dL). Secondary outcomes included time in tight range (TiTR, 70-140 mg/dL), time above and below range, glucose variability, insulin dose, achievement of ISPAD glycaemic targets and safety. HbA1c was measured at baseline, 3 and 6 months. RESULTS: Seventy-six participants (mean age 13.3 ± 3.2 years) completed follow-up. Mean TIR increased from 59.0% ± 15.6% at baseline to 74.2% ± 8.9% at 1 month and remained significantly higher at 3 and 6 months (all p < 0.05). TiTR significantly improved, whilst time above range decreased and time below range remained stable. More than half of participants achieved the ISPAD target of TIR > 70% at 6 months. Mean sensor glucose and glucose variability declined, and HbA1c decreased from 7.4% ± 0.8% to 6.9% ± 0.7% at 3 and 6 months (all p < 0.05). No episodes of severe hypoglycaemia or diabetic ketoacidosis were observed. CONCLUSIONS: In routine paediatric care, use of this tubeless AID system was associated with rapid and sustained improvements in glycaemic control without increased hypoglycaemia. TRIAL REGISTRATION: Clinicaltrials.gov: NCT07425912.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.

Titre Crossref
Real‐World Effectiveness and Safety of a Tubeless Automated Insulin Delivery System With an Adaptive Control Algorithm ( <scp>APGO</scp> ) in Children and Adolescents With Type 1 Diabetes: A Multicentre Observational Study
Date Crossref
23/07/2026
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Diabetes Management and ResearchPancreatic function and diabetesDiabetes and associated disorders

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.